Research on Ringworm in Unani Medicine

Phase 2

Not yet recruiting

Conditions: Other specified local infections of the skin and subcutaneous tissue,

Registration Number: CTRI/2023/06/053844

Lead Sponsor: National Institute of Unani Medicine

Brief Summary: Dermatophytes are known to cause superficial mycosis in animals and humans owing to their ability to destroy keratin present in skin, hair and nails leading to the development of dermatophytosis. One of the dermatophytosis is ringworm (Tinea corporis) infection which is known to affect approximately 20-25% of the global population. These infections are common in the tropics due to high levels of humidity, overpopulation and poor hygiene.

The global prevalence of dermatophytosis is estimated to be 20%. The prevalence of dermatophytes has increased tremendously in the last few decades due to various factors like climate change, socio-economic and occupational situations.

It has been observed recently that there has been widespread resistance to various antifungal agents used in conventional doses with an increase in relapse rates prompting a need to find effective first-line antifungal drugs and appropriate dosages and drug schedules to achieve maximum results with fewer relapses. The most common side effects of antifungal drugs are gastric upset, headache, altered taste, altered liver function tests and rash, even cause blood dyscrasias and hepatitis.

Likewise, long-term use of steroid creams can make ringworm worse by allowing them to spread along making the immune system weak and in some rare cases, it allows the fungus that causes ringworm to invade deeper into the skin and cause the more serious condition.

In the Unani system of medicine, several formulations are indicated for the management of tinea corporis(Qooba )and all such formulations are tested for centuries and data on their effectiveness is available. So the present study has been designed to validate the effectiveness of some of the formulations on scientific rationale.

Detailed Description: Not available

Recruitment & Eligibility

Status: Not Yet Recruiting

Sex: All

Target Recruitment: 40

Inclusion Criteria

Clinically diagnosed cases of Tinea Corporis with less than or equal to 3% body surface area (calculated by the palm rule)Patients whose KOH is positive.
Patient of either gender.
Age group 18-60 years.
4).Patient with controlled diabetes.

Exclusion Criteria

1.Known cases of tinea corporis on medication one month prior 2.
Patients of T.
Corporis with more than 3% body surface area.
Patients whose KOH is negative.
Patients below and above the age of 18 and 60 years respectively.
Patients suffering from concomitant skin diseases like psoriasis & Eczema and other types of tinea like T.
Facei, T.Capitis, T.Unguum, T.Manuum.
Pregnant & Lactating Women.
Known history of impaired hepatic, renal or cardiovascular functions in patients.
Uncontrolled cases of Diabetes and other immunocompromised patients.

Study & Design

Study Type: Interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Primary End Points:	3 Weeks
complete clearance among groups at the end of the intervention	3 Weeks
Secondary End Points:	3 Weeks
a) Comparison of achieved clinical cure among groups at the end of the intervention	3 Weeks

Secondary Outcome Measures

Name	Time	Method
Secondary End Points:	a) Comparison of achieved clinical cure among groups at the end of the intervention

Trial Locations

Locations (1): National Institute Of Unani Medicine
🇮🇳
Bangalore, KARNATAKA, India
National Institute Of Unani Medicine
🇮🇳Bangalore, KARNATAKA, India
Dr Sana Hasan
Principal investigator
9129794978
stillarsana@gmail.com